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http://www.lipidworld.com/content/12/1/135RESEARCH Open AccessApolipoprotein M T-778C polymorphism is
associated with serum lipid levels and the risk of
coronary artery disease in the Chinese
population: a meta-analysis
Zhi Zhang2†, Guang Chu2† and Rui-Xing Yin1*Abstract
Background: The apolipoprotein M (APOM) T-778C gene polymorphism has been associated with serum lipid
levels and the risk of coronary artery disease (CAD), but the results are inconclusive. The purpose of this meta-
analysis was to detect the association between the APOM T-778C polymorphism and serum lipid levels and the risk
of CAD in the Chinese population.
Methods: Databases of MEDLINE, EMBASE, the Cochrane Library and CNKI were systematically searched. Data were
extracted using standardized methods. The association was assessed by mean difference (MD) with 95% confidence
intervals (CI) or odds ratio (OR) with 95% CI.
Results: Ten studies with 4,413 patients were included in this meta-analysis. Pooled effects indicated that CT+CC
group had higher levels of total cholesterol (TC) (MD:-0.36, 95% CI: -0.53 – -0.19, P < 0.0001) and low-density
lipoprotein cholesterol (LDL-C) (MD: -0.08, 95% CI: -0.16 – -0.01, P = 0.03) than TT group. There was no difference in
the levels of triglyceride (MD: 0.06, 95% CI: -0.04 – 0.15, P = 0.22) and high-density lipoprotein cholesterol (MD: 0.00,
95% CI: -0.03–0.03, P = 0.93) between TT and CT+CC groups. Pooled effects showed that CAD group had higher
CT+CC genotype frequency than control group (OR: 1.97, 95% CI: 1.62–2.39, P < 0.00001; heterogeneity test x2 =
2.96, P = 0.71, I2 = 0%).
Conclusions: The results of the current meta-analysis show that the CT+CC group has higher levels of TC and LDL-
C than the TT group. Moreover, there is also a prominent association between APOM T-778C polymorphism and
the risk of CAD in the Chinese population, the CT+CC genotype is associated with increased risk of CAD.Introduction
Coronary artery disease (CAD) continues to be the lead-
ing cause of morbidity and mortality among adults now-
adays [1]. Many studies have proved that serum lipid
concentrations are strongly correlated to the risk of CAD,
such as a low concentration of high-density lipoprotein
cholesterol (HDL-C) [2,3], and high levels of total choles-
terol (TC) [4], triglyceride (TG) [5], low-density lipopro-
tein cholesterol (LDL-C) [6], and apolipoprotein (Apo) B* Correspondence: yinruixing@163.com
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reproduction in any medium, provided the or[7,8]. However, it is widely accepted that dyslipidemia and
CAD are caused by multiple environmental and genetic
factors and their interactions [9].
Association of different genes and CAD and/or dys-
lipidemia has been widely examined. Recently, apolipo-
protein M (APOM) gene has been reported relevant to
CAD and dyslipidemia [10]. APOM gene is located in
p21.31 on human chromosome 6 (chromosome 17, in
mouse). Human APOM cDNA (734 base pairs) encodes
188-amino acid residue-long protein [11]. APOM is
mainly associated with HDL-C and lesser extent with
TG-rich lipoproteins, ApoB-containing lipoproteins, low
and very low-density lipoprotein (VLDL). It has been
also demonstrated that APOM plays an important roleLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.




1) Is the case definition adequate?
a) yes, with independent validation ☆
b) yes, eg record linkage or based on self reports
c) no description
2) Representativeness of the cases
a) consecutive or obviously representative series of cases ☆
b) potential for selection biases or not stated
3) Selection of controls
a) community controls ☆
b) hospital controls
c) no description
4) Definition of controls
a) no history of disease (endpoint) ☆
b) no description of source
Comparability
1) Comparability of cases and controls on the basis of the
design or analysis
a) study controls for the most important factor ☆
b) study controls for any additional factor ☆
Exposure
1) Ascertainment of exposure
a) secure record (eg surgical records) ☆
b) structured interview where blind to case/control status ☆
c) interview not blinded to case/control status
d) written self report or medical record only
e) no description




a) same rate for both groups ☆
b) non respondents described
c) rate different and no designation
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expressed in liver and in kidney [13].
Recent studies have showed that the APOM T-778C
(rs805296) is valid in the Han Chinese and associated
with serum lipid levels and the risk of CAD, but the re-
sults are inconclusive [14-23]. It may be partially due to
the fact that the APOM gene was a minor gene for risk
of dyslipidemia and/or the relatively small sample size in
each of the published studies. Therefore, we performed a
meta-analysis of the published studies to derive a more
precise estimation of the association.
Materials and methods
Search strategy
All studies that reported the association between the
APOM T-778C polymorphism and serum lipid levels
and/or the risk of CAD and published in English or in
Chinese before May, 2013 were identified by comprehen-
sive computer-based searches of MEDLINE via PubMed
(from 1950 to May 2013), EMBASE (1980 to May 2013),
the Cochrane Library database (Cochrane Central Register
of Controlled Trials, from 1991 to May 2013) and China
National Knowledge Infrastructure (CNKI). The following
key words were used: “Apolipoprotein M,” “APOM,”
“rs805296 (T-778C) polymorphism”, “dyslipidemia” and
“serum lipid level”, “coronary artery disease”. The above
search strategy described was used to obtain titles and
abstracts of studies that may have been relevant to this re-
view. The titles and abstracts were screened independently
by two authors (Z Zhang and G Chu), who discarded
studies that were not applicable. When multiple reports
from the same patients were found, only the study with
the most complete data set was included in the meta-
analysis. But duplicate patients of different articles that
have different types of data of outcomes were included
both. Any disagreements were arbitrated by discussion
with the third reviewer (R-X Yin).
Included and excluded studies
Two investigators reviewed all identified studies inde-
pendently to determine whether an individual study was
eligible for inclusion. The selection criteria for studies to
be considered for this meta-analysis were as follows: (1)
case–control studies published in peer-reviewed journals
with full available text in English or in Chinese; (2) the
APOM gene T-778C polymorphism and serum lipid
levels and the risk of CAD; (3) reporting at least one
relevant outcomes of association between genotype and
serum lipid levels and the risk of CAD, serum lipid levels
including TC, HDL-C, LDL-C, and TG. Excluded stud-
ies: (1) studies in which it was not possible to extract
data from the published results and from the authors;
and (2) studies that did not report appropriate outcomes
were also excluded.Types of outcome measures
(1) Relationship between serum lipid parameters and ge-
notypes; (2) Relationship between the risk of CAD and
genotypes; (3) Genotype freguency: TT and CT+CC; (4)
Serum lipid parameters: TC, TG, HDL-C, and LDL-C.
Data extraction and management
Two investigators (Z Zhang and G Chu) independently
extracted data according to the author details and the
following information was extracted from each study:
first author, year of publication, sample size, diagnostic
criteria, study design, characteristics of controls, geno-
type information (number of genotypes, genotyping
Figure 1 Flow chart showing study selection process.
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relationship between genotypes and serum lipid parame-
ters and the risk of CAD. Discrepancies were resolved
by discussion. When repeated publications of the same
trial were identified, data were extracted from the re-
peated publications and reported as a single trial.
Quality assessment
The Newcastle-Ottawa Scale (NOS) [24] was used to
assess the quality of each included study of the CAD
group. Eight items were contained in the NOS (Table 1).
It was categorized into three dimensions including selec-
tion, comparability, and exposure for case–control stud-
ies. Four, one and three items were contained in the
selection, comparability and exposure; respectively. A
star system was used to allow a semi-quantitative assess-
ment of the study quality. A study can be awarded a
maximum of one star for each numbered item within
the selection and exposure categories. A maximum of
two stars can be given for comparability. The NOS
ranges from zero up to nine stars. High-, medium-, andpoor-quality studies should be achieved more than
seven, four to six, and less than four stars; respectively.
Statistical analysis
Allele frequencies of each study were determined by the
allele counting method. Hardy–Weinberg equilibrium
(HWE) for each single nucleotide polymorphism was
assessed for the controls in each study using Pearson’s
Square (P > 0.05) [24]. We carried out statistical analysis
by the Review Manager software 5.1.0 (updated in March
2011 by the Cochrane Collaboration). We examined the
contrast of genetic model (TT vs. CT+CC) in serum lipid
levels and genetic model (CT+CC vs. TT+CT+CC) in the
risk of CAD. Continuous variables were expressed as
mean difference (MD) with 95% confidence intervals (CI).
Dichotomous outcomes of the numbers of CT+CC and
TT+CT+CC genotypes in CAD/control values were
expressed as odd ratio (OR) with 95% CI. The pooled
effects were calculated using fixed effects models when
there was no significant heterogeneity but the random
effects model was analyzed to ensure robustness of the







Case Control Case Control
Jiao et al. [15] 2007 118/225 61.8 ± 11.4 60.4 ± 12.7 CAD patients had at least 30% stenos is determined
angiographically in at least one of the major
segments of coronary arteries, the right coronary
artery, left circumflex, or left anterior descending
arteries.
Hospital-based PCR-RFLP TC,TG, HDL-C,
LDL-C
Zhao et al. [21] 2011 314/389 64.43 ± 8.48 63.93 ± 6.86 Ischemic stroke patients included having a sudden
loss of global or focal cerebral function, and
corresponding infarction confirmed by brain
imaging with a computed tomography scan and/or
magnetic resonance imaging.
Hospital-based PCR, SNaPshot TC,TG, HDL-C,
LDL-C
Zheng et al. [22] 2009 126/118 62.5 ±9.4 63.0 ±10.8 Patients that diagnosed as CAD according to the
results of angiography (a lesion was classed as
being significant when stenosis was >50%).
Hospital-based real-time PCR TC,TG, HDL-C,
LDL-C, )
Niu et al. [18] 2006 170/156 55.5 ± 13.2 56.2 ± 9.7 T2D patients were diagnosed according to the
criteria of the World Health Organization (1999).
Hospital-based PCR-RFLP TC, TG
Wu et al. [20] 2009 117/316 22.8 ± 14.5 63.1 ± 9.7 T1D patients were diagnosed according to the
criteria of the World Health Organization (1999)
with positive of anti-islet antibodies result in
inability to produce insulin.
Hospital-based PCR-RFLP TC, TG




Huang et al. [14] 2009 220/195 64.3 ± 11.1 59.0 ± 10.1 Patients that diagnosed as CAD according to the
results of clinical symptoms, angiography,
electrocardiogram and echocardiography.
Hospital-based PCR-RFLP TC, TG
Wang et al. [19] 2009 45/60 51.4 ± 6.2 52.6 ± 8.6 Patients diagnosed of CAD based on the criteria of
the World Health Organization (1979).
Hospital-based PCR-RFLP TC,TG, LDL-C
Zhang et al. [23] 2012 675/636 56.4 ± 9.9 55.8 ± 10.4 Patients diagnosed of CAD based on the criteria of




Ma et al. [16] 2011 112/168 57.9 ± 10.2 56.2 ±9.4 Patients that diagnosed as CAD according to the
results of angiography (≥50% stenos in at least one
of the major segments of coronary arteries).
Hospital-based Allele-specific PCR TC,TG, HDL-C,
LDL-C
CAD Coronary artery disease, T2D Type 2 diabetes mellitus, T1D Type 1 diabetes mellitus, PCR Polymerase chain reaction, RFLP Restriction fragment length polymorphism, TC Total cholesterol, TG Triglycerides, HDL-C





















Figure 2 Forest plot of the association between APOM T-778C polymorphism and serum TC levels. (genetic model: TT vs. CT+CC).
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dom effects models when there was significant heterogen-
eity but the fixed effects model was analyzed to ensure
robustness of the model chosen and susceptibility to out-
liers. The point estimate of the MD or OR was considered
statistically significant at the 2-tailed P ≤ 0.05 level. Het-
erogeneity was analyzed using a chi-square test on N-1
degrees of freedom [25]. I2 values of 25%, 50% and 75%
correspond to low, medium and high levels of heterogen-
eity; respectively. Sensitivity analyses were performed
omitting a single study at a time or analyzed anotherFigure 3 Forest plot of the association between APOM T-778C polymmodel chosen. If enough studies were identified, funnel
plots were to be used to investigate reporting biases [26].
Results
Characteristics of included studies
Ten studies [14-23], 5 in English [15,18,20-22] and 5 in
Chinese [14,16,17,19,23] met the included criteria for
this meta-analysis (Figure 1). All of the studies had been
approved by the Ethics Committee of their affiliations,
in accordance with the Helsinki Declaration of 1975 as
revised in 1983, and all subjects had given informedorphism and serum TG levels. (genetic model: TT vs. CT+CC).
Figure 4 Forest plot of the association between APOM T-778C polymorphism and serum LDL-C levels. (genetic model: TT vs. CT + CC).
Figure 5 Forest plot of the association between APOM T-778C polymorphism and serum HDL-C levels. (genetic model: TT vs. CT+CC).
Figure 6 Forest plot of the association between APOM T-778C polymorphism and CAD risk by comparison of CAD and control groups.
(genetic model: CT+CC vs. TT+CT+CC).
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Table 3 Quality assessment for all the included studies of
the CAD
First author Publishing year Selection Comparability Exposure
Jiao [15] 2007 ☆☆☆ ☆☆ ☆☆☆
Huang [14] 2009 ☆☆☆ - ☆☆☆
Zheng [22] 2009 ☆☆☆ ☆ ☆☆☆
Ma [16] 2011 ☆☆ ☆ ☆☆
Zhang [23] 2012 ☆☆☆☆ - ☆☆
Wang [19] 2009 ☆☆☆ - ☆☆
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Committee of the First Affiliated Hospital, Guangxi
Medical University. Among them, six of the eligible
studies contained data in lipid parameters on two differ-
ent groups [14-16,18,21,22], and we treated the different
groups as independent. Therefore, a total of 16 separate
comparisons were finally included in our meta-analysis.
The main characteristics of each study are shown in
Table 2. Nine studies contained the data of TG and TC
and there were 15 separated comparisons; six studies
contained the levels of LDL-C and there were 10 sepa-
rated comparisons; five studies included the concentra-
tions of HDL-C and there were 9 separated comparisons;
and six studies contained the data of CAD for this meta-
analysis (Figures 2, 3, 4, 5 and 6). A total of 4,413 people
were included in this study. The relationship between lipid
parameters and genotypes in 3,102 people, and between
the risk of CAD and genotypes in 2,698 subjects was ana-
lyzed; respectively. All the eligible studies were conducted
in the Chinese population.
The quality of all included studies was assessed by
NOS (Table 3). Most studies were of medium or high
quality in terms of selection and exposure. However, as
for comparability, the quality was relativity low, since




Jiao et al. [15] 2007 86 (72.9) 29 (24.6) 3 (2.5)
Zhao et al. [21] 2011 221 (70.4) 86 (27.4) 7 (2.2)
Zheng et al. [22] 2009 99 (78.6) 25 (19.8) 2 (1.6)
Niu et al. [18] 2006 135 (79.4) 34 (20.0) 1 (0.6)
Wu et al. [20] 2009 140 (79.1) 37 (20.9) 0 (0.0)
Mo et al. [17] 2011 - - -
Huang et al. [14] 2009 145 (65.9) 66 (30.0) 9 (0.41
Wang et al. [19] 2009 29 (64.4) 15 (33.3) 1 (2.2)
Zhang et al. [23] 2012 530 (78.5) 135 (20.0) 10 (1.5
Ma et al. [16] 2011 80 (71.4) 30 (26.8) 2 (1.8)Frequencies of the genotype
Frequencies of the APOM T-778C genotypes in each
group and all P-values of HWE testing are shown in
Table 4. The genotype distribution of the APOM T-778C
polymorphism in all eligible studies was consistent with
HWE (P > 0.05).
Outcomes of lipid levels
As shown in Figure 2, the pooled effects indicated that
CT+CC group had higher levels of TC than TT group
(MD:-0.36, 95% CI: -0.53 – -0.19, P < 0.0001; heterogen-
eity test x2 = 56.34, P < 0.00001, I2 = 75%). There was no
difference in the levels of TG between TT and CT+CC
groups (MD: 0.06, 95% CI: -0.04–0.15, P = 0.22; heterogen-
eity test x2 = 21.76, P = 0.08, I2 = 36%; Figure 3). CT+CC
group had higher levels of LDL-C than TT group (MD:
-0.08, 95% CI: -0.16– -0.01, P = 0.03; heterogeneity test
x2 = 10.81, P =0.29, I2 = 17%; Figure 4). There was no dif-
ference in the levels of HDL-C between TT and CT+CC
groups (MD: 0.00, 95% CI: -0.03–0.03, P= 0.93; heterogeneity
test x2= 10.33, P= 0.24, I2= 23%; Figure 5).
Outcomes of the risk of CAD
The eligible compared groups were pooled with fixed
effects models and the data of CT+CC and CC+CT+TT
groups in the CAD/control value and the pooled effects
are shown in Figure 6. Pooled effects showed that CAD
group had higher CT+CC genetype frequency than con-
trol group (OR: 1.97, 95% CI: 1.62–2.39, P < 0.00001;
heterogeneity test x2 = 2.96, P = 0.71, I2 = 0%).
Sensitivity analysis
Sensitivity analyses were performed to assess the contribu-
tion of each study to the pooled estimate and by excluding
individual studies one at a time and recalculating the
pooled MD or OR estimates for the remaining studies.s in different populations included in the meta-analysis




194 (86.2) 31 (13.8) 0 (0.0) 0.267
318 (81.7) 67 (17.3) 4 (1.0) 0.823
100 (84.7) 18 (15.3) 0 (0.0) 0.370
138 (88.5) 18 (11.5) 0 (0.0) 0.444
284 (89.9) 32 (10.1) 0 (0.0) 0.358
366 (85.1) 62 (14.4) 2 (0.05) 0.717
) 150 (76.9) 41 (21.0) 4 (2.1) 0.548
51 (85.0) 9 (15.0) 0 (0.0) 0.530
) 556 (87.5) 74 (11.6) 6 (0.9) 0.052
145 (86.3) 21 (12.5) 2 (1.2) 0.231
Figure 7 Funnel plot of the association between APOM T-778C polymorphism and serum LDL-C levels. (genetic model: TT vs. CT + CC).
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less than 100 patients in each group did not substan-
tially change the pooled point estimate, which indicates
the reliability of our results. What is more, performing
transition of model also did not substantially change the
pooled point estimate.
Heterogeneity analysis
For the outcomes of TC, the I2 value of heterogeneity
was greater than 50% and the heterogeneity test: P value
was less than 0.10 in model TT vs. CT+CC in the overall
populations, which indicated statistically significant het-
erogeneity among the studies. In order to explore the
sources of heterogeneity, the studies were stratified by
cases and controls and subgroup analyses were performed.Figure 8 Funnel plot of the association between APOM T-778C polymHowever, heterogeneity still existed in the outcomes of
TC (Figure 2).
Publication bias
The funnel plot and Egger test were performed to assess
the publication bias of literatures in all comparison
models. No visual publication bias was found in the
funnel plot (Figures 7 and 8).
Discussion
Association of different genes in relation to the predis-
position of CAD has been widely examined. It may
conclude that CAD is both multifactorial and polygenic
in nature. The disorders of lipid profile are important
risk factors involved in this process [27]. A variety oforphism and serum HDL-C levels. (genetic model: TT vs. CT + CC).
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factors of CAD, including those involved in lipid metab-
olisms. ApoM is one of the latest additions to the apoli-
poprotein family [28]. Over expression of ApoM had a
protective effect against atherosclerosis [12]. Many in-
vestigators carried out case–control studies in order to
determine the association between this polymorphism
and serum lipid levels or the risk of CAD, but the results
are inconclusive. This may be due to a small sample size.
The characteristic of a meta-analysis is to obtain a more
competitive result by combining the comparable studies,
increasing the sample size and statistical power [29].
The results of our meta-analysis showed that the CT+CC
group had higher levels of TC and LDL-C than the TT
group, and there was no difference in the levels of HDL-C
and TG between the TT and CT+CC groups. Moreover,
the CT+CC genotype was associated with increased risk
of CAD.
In the present study, we included ten studies and all of
the subjects were the Chinese populations. Baseline
characteristics of two comparison groups of included
studies were substantially similar. All included studies
were consistent with HWE. The quality of the included
studies that associated between polymorphism and CAD
risk was assessed by NOS and most studies were of
medium or high quality. In addition, heterogeneities of
pooled effects of HDL-C, LDL-C and CAD were low.
MD of total of TC ( P < 0.0001) and OR of total of CAD
risk (P < 0.00001) were large effect. All these made our
conclusion more robust.
Heterogeneity analysis showed that the polymorphism
suggested significant heterogeneity in the outcomes of
TC in the overall populations. To explore the sources of
heterogeneity, we performed subgroup analyses, but het-
erogeneity still existed in the outcomes of TC. This may
be due to China being a large country with multiethnic
country. Different groups of the included studies had
different genetic background and environmental factors.
It is well known that both serum lipid levels and CAD
are affected by genetic and environmental factors, such
as dietary patterns, lifestyle, obesity, physical inactivity.
Moreover, pharmaceuticals, age, gender, hypertension
are also associated with serum lipid levels [30].
Some limitations of this meta-analysis should be
discussed. First, this meta-analysis focused only on pa-
pers published in English and Chinese and the ones that
reported in other languages may bias the present results.
Second, the meta-analysis cannot be corrected the bias
of each study in the outcomes of TC, and may generate
a statistical conclusion with more power and precision.
In addition, gene-gene and gene-environment interac-
tions should also be considered in the analysis.
Therefore, it is necessary to conduct large sample stud-
ies using standardized unbiased genotyping methods,homogeneous CAD patients and well- matched controls.
Moreover, gene-gene and gene-environment interactions
should also be considered in the analysis. Such studies tak-
ing these factors into account may eventually lead to bet-
ter, more comprehensive understanding of the association
between the APOM T-778C polymorphism and serum
lipid levels or the risk of CAD.
Conclusion
The results of the current meta-analysis showed that the
CT+CC group had higher levels of TC and LDL than
the TT group, and there was no difference in the levels
of HDL and TG between the TT and CT+CC groups.
Moreover, there a prominent association between the
APOM T-778C polymorphism and the risk of CAD in
the Chinese population, and the CT+CC genotype was
associated with increased risk of CAD.
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